miR‐941 in extracellular vesicles confers anlotinib resistance via Keap1/Nrf2 axis and represents a therapeutic target in non‐small cell lung cancer
Clinical and Translational Medicine · 2026-06 · 16 (6)
DOI: 10.1002/ctm2.70721 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 15.06.2026. Verfasst von Aimi Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao To…. Hauptthemen laut MEDLINE: Kelch-Like ECH-Associated Protein 1, NF-E2-Related Factor 2, Carcinoma, Non-Small-Cell Lung, MicroRNAs. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Mechanism of YAP m5C Modification Promoting, Generation of Neoantigens and Immune Escape and Its Impact on Immunotherapy.
Abstract (Originalsprache)
Background
Anlotinib is a multitargeted tyrosine kinase inhibitor for the treatment of advanced non‐small cell lung cancer (NSCLC), though its therapeutic efficacy is constrained by acquired resistance. Although elevated extracellular vesicle (EV)‐derived miR‐941 correlates with anlotinib resistance, its functional role remains unexplored. Here, we provide evidence that EV‐delivered miR‐941 mediates this resistant phenotype.
Methods
Functional experiments (gain‐ and loss‐of‐function) in A549 and H1299 cells assessed viability, apoptosis and migration. The miR‐941 / Keap1 interaction was validated using dual‐luciferase assays. In vivo resistance was evaluated using wild‐type and Keap1 3'UTR‐mutant xenograft models. Clinical relevance and survival outcomes were analysed in tumour tissues from anlotinib‐treated patients.
Results
EV‐derived miR‐941 was significantly upregulated in anlotinib‐resistant patients. Mechanistically, miR‐941 directly targeted the Keap1 3′UTR, suppressing Keap1 protein and activating the Nrf2 signalling pathway. This axis inhibited apoptosis, upregulated anti‐apoptotic proteins (Bcl‐2, Mcl‐1), and promoted malignant phenotypes in vitro. Crucially, in vivo anlotinib resistance induced by miR‐941 overexpression was completely abrogated by mutating the Keap1 binding site. Clinical samples confirmed elevated miR‐941 and a molecular signature consistent with Keap1 downregulation and Nrf2 activation in resistant tumours. Furthermore, high expression of miR‐941 was strongly associated with shorter progression‐free survival and overall survival.
Conclusion
In this study, we identified EV‐derived miR‐941 as a key driver of anlotinib resistance via the Keap1 /Nrf2 pathway. It represents a promising non‐invasive predictive biomarker and serves as a candidate therapy target for overcoming drug‐resistant NSCLC. Key points EV‐derived miR‐941 as a key driver of anlotinib resistance via the Keap1/Nrf2 pathway represent a promising non‐invasive predictive biomarker and a potential therapeutic target for overcoming resistance in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- Mechanism of YAP m5C Modification Promoting
- Generation of Neoantigens and Immune Escape and Its Impact on Immunotherapy
- Shanghai Municipal Health Commission Health Policy Research Project
- Study on the Health Management of Elderly Lung Cancer Patients' Pulmonary Function Characteristics and Postoperative Eight-Section Qigong Rehabilitation Traini…
Zitieren
APA
Huang, A., Li, X., Wu, E., Hao, M., Wang, W., & Xia, J. (2026). miR‐941 in extracellular vesicles confers anlotinib resistance via Keap1/Nrf2 axis and represents a therapeutic target in non‐small cell lung cancer. Clinical and Translational Medicine, 16(6). https://doi.org/10.1002/ctm2.70721
Vancouver
Huang A, Li X, Wu E, Hao M, Wang W, Xia J. miR‐941 in extracellular vesicles confers anlotinib resistance via Keap1/Nrf2 axis and represents a therapeutic target in non‐small cell lung cancer. Clinical and Translational Medicine. 2026;16(6). doi:10.1002/ctm2.70721
BibTeX
@article{Huang2026,
author = {Huang, Aimi and Li, Xiaoqi and Wu, Erpeng and Hao, Menglan and Wang, Weimin and Xia, Jinjing},
title = {miR‐941 in extracellular vesicles confers anlotinib resistance via Keap1/Nrf2 axis and represents a therapeutic target in non‐small cell lung cancer},
journal = {Clinical and Translational Medicine},
year = {2026},
volume = {16},
number = {6},
doi = {10.1002/ctm2.70721}
}
EUVIMED